MARKET

THOR

THOR

Synthorx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

67.99
0.00
0.00%
Delisted 09:30 01/27 EST
OPEN
68.00
PREV CLOSE
67.99
HIGH
68.01
LOW
67.99
VOLUME
698.15K
TURNOVER
--
52 WEEK HIGH
71.90
52 WEEK LOW
11.05
MARKET CAP
1.86B
P/E (TTM)
-35.2517
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of THOR and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 3 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

THOR News

  • Sanofi finalizes Synthorx buy
  • seekingalpha.4d ago
  • IBKC, THOR, TIF, and AMTD SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts
  • GlobeNewswire.01/09 18:15
  • INVESTOR ALERT: Monteverde & Associates PC Reminds Investors of its Ongoing Investigation Regarding the Transaction
  • ACCESSWIRE.01/09 15:15
  • READ NOW: Monteverde & Associates PC Reminds Investors of its Ongoing Investigation Regarding the Merger
  • ACCESSWIRE.01/07 19:00

More

Industry

Biotechnology & Medical Research
-0.88%
Pharmaceuticals & Medical Research
-0.51%

Hot Stocks

Name
Price
%Change

About THOR

Synthorx, Inc. is a biopharmaceutical company. The Company is focused on prolonging and improving the lives of people suffering from cancer and autoimmune disorders. Its platform technology expands the genetic code by adding a new deoxyribonucleic acid (DNA) base pair and is designed to create optimized biologics, which is referred as Synthorins. The Company’s lead product candidate, THOR-707, is a variant of IL-2 designed to kill tumor cells by increasing CD8+ T and natural killer (NK), cells without causing vascular leak syndrome (VLS), observed with IL-2 (aldesleukin). Its cytokine Synthorin programs, including IL-2, IL-10 and IL-15 for the treatment of cancer, and another IL-2 Synthorin program for the treatment of autoimmune disorders.
More

Webull offers Synthorx Inc (THOR) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.